R
Roger A'Hern
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 174
Citations - 19328
Roger A'Hern is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 68, co-authored 173 publications receiving 17915 citations. Previous affiliations of Roger A'Hern include St Lukes Episcopal Hospital.
Papers
More filters
Journal ArticleDOI
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo,Suzanne Carreira,Shahneen Sandhu,Susana Miranda,Helen Mossop,Raquel Perez-Lopez,Daniel Nava Rodrigues,Dan R. Robinson,Aurelius Omlin,Nina Tunariu,Gunther Boysen,Nuria Porta,Penny Flohr,Alexa Gillman,Ines Figueiredo,Claire Paulding,George Seed,Suneil Jain,Christy Ralph,Andrew Protheroe,Syed A. Hussain,Robert Jones,Tony Elliott,Ursula McGovern,Diletta Bianchini,Jane C. Goodall,Zafeiris Zafeiriou,Chris T. Williamson,Roberta Ferraldeschi,Ruth Riisnaes,Bernardette Ebbs,Gemma Fowler,Desamparados Roda,Wei Yuan,Yi-Mi Wu,Xuhong Cao,Rachel Brough,Helen Pemberton,Roger A'Hern,Amanda Swain,Lakshmi P. Kunju,Rosalind A. Eeles,Gerhardt Attard,Christopher J. Lord,Alan Ashworth,Mark A. Rubin,Karen E. Knudsen,Felix Y. Feng,Arul M. Chinnaiyan,Emma Hall,Johann S. de Bono +50 more
TL;DR: Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate.
Journal ArticleDOI
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett,Torsten O. Nielsen,Roger A'Hern,John M. S. Bartlett,R. Charles Coombes,Jack Cuzick,Matthew J. Ellis,N. Lynn Henry,Judith Hugh,Tracy Lively,Lisa M. McShane,Soon Paik,Frédérique Penault-Llorca,Ljudmila Prudkin,Meredith M. Regan,Janine Salter,Christos Sotiriou,Ian E. Smith,Giuseppe Viale,Jo Anne Zujewski,Daniel F. Hayes +20 more
TL;DR: Comprehensive recommendations on preanalytical and analytical assessment, and interpretation and scoring of Ki67 were formulated based on current evidence, geared toward achieving a harmonized methodology, create greater between-laboratory and between-study comparability, and allow earlier valid applications of this marker in clinical practice.
Journal ArticleDOI
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C.C. Fong,Timothy A. Yap,D. S. Boss,Craig P. Carden,Marja Mergui-Roelvink,Charlie Gourley,Jacques De Greve,Jan Lubinski,Susan Shanley,Christina Messiou,Roger A'Hern,Andrew Tutt,Alan Ashworth,John F. Stone,James Carmichael,Jan H.M. Schellens,Johann S. de Bono,Stan B. Kaye +17 more
TL;DR: Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is associated with platinum sensitivity, a significant association between the clinical benefit rate and platinum-free interval across the platinum-sensitive, resistant, and refractory subgroups.
Journal ArticleDOI
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard,Alison Reid,Roger A'Hern,Chris Parker,Nikhil Babu Oommen,Elizabeth Folkerd,Christina Messiou,L Rhoda Molife,G. Maier,Emilda Thompson,David Olmos,Rajesh Sinha,Gloria Lee,Mitch Dowsett,Stan B. Kaye,David P. Dearnaley,Thian Kheoh,Arturo Molina,Johann S. de Bono +18 more
TL;DR: YP17 blockade by abiraterone acetate results in declines in PSA and CTC counts and radiologic responses, confirming that CRPC commonly remains hormone driven.
Journal ArticleDOI
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Gerhardt Attard,Joost F. Swennenhuis,David Olmos,Alison Reid,Elaine Vickers,Roger A'Hern,Rianne Levink,Frank A. W. Coumans,Joana Moreira,Ruth Riisnaes,Nikhil Babu Oommen,George Hawche,Charles Jameson,Emilda Thompson,Ronald Sipkema,Craig P. Carden,Chris Parker,David P. Dearnaley,Stan B. Kaye,Colin Cooper,Arturo Molina,Michael E. Cox,Leon W.M.M. Terstappen,Johann S. de Bono +23 more
TL;DR: A significant association between ERG rearrangements in therapy-naive tumors, CRPCs, and CTCs and magnitude of prostate-specific antigen decline is reported and indicates that hormone-regulated expression of ERG persists in CRPC.